• Bayer presents New Analyses for Vitrakvi® americanpharmaceuticalreview
    May 17, 2019
    Bayer announced findings from new analyses and data for Vitrakvi® (larotrectinib), which is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tropomyosin receptor kinase (NTRK) gene fusion without ...
PharmaSources Customer Service